First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

unknow

★ 5.0 · 21 reads

Request Code
ZLIB.IO18490953
Published
2022
Pages
1
Language
Unknown